替莫唑胺剂量调节差异性影响T细胞对免疫检查点抑制的反应
在GL261和KR158小鼠胶质瘤模型中,标准剂量替莫唑胺(50 mg/kg×5天)上调淋巴细胞LAG-3和TIM-3等T细胞耗竭标志物,而节拍剂量(25 mg/kg×10天)未见此现象;标准剂量替莫唑胺削弱PD-1抗体治疗的生存获益,节拍剂量则保留该获益。
要点
- 标准剂量替莫唑胺上调淋巴细胞LAG-3和TIM-3表达,节拍剂量未观察到此变化。
- 节拍剂量替莫唑胺联合PD-1抗体降低肿瘤浸润淋巴细胞的耗竭标志物,标准剂量联合未见此效应。
- 标准剂量替莫唑胺削弱PD-1抗体在小鼠同种异体颅内胶质瘤模型中的生存获益,节拍剂量保留该获益。
核心结论
- 替莫唑胺的剂量调节对外周和瘤内免疫微环境产生差异性影响。
研究设计与样本
- 在GL261和KR158小鼠胶质瘤模型中,比较节拍剂量替莫唑胺(25 mg/kg×10天)或标准剂量替莫唑胺(50 mg/kg×5天)治疗后的免疫功能和免疫检查点抑制的抗肿瘤疗效。
主要发现
- 标准剂量替莫唑胺治疗导致淋巴细胞中LAG-3和TIM-3等T细胞耗竭标志物上调,节拍剂量替莫唑胺未见此现象。
- 替莫唑胺联合PD-1抗体治疗时,节拍剂量替莫唑胺/PD-1抗体组肿瘤浸润淋巴细胞的耗竭标志物减少,标准剂量替莫唑胺/PD-1抗体组未观察到此变化。
- 在小鼠同种异体颅内胶质瘤模型中,PD-1抗体治疗的生存获益在加入标准剂量替莫唑胺后被削弱。
- 加入节拍剂量替莫唑胺至PD-1抑制时,保留了单独PD-1抗体治疗所见的生存获益。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The changes induced in host immunity and the tumor microenvironment by chemotherapy have been shown to impact immunotherapy response in both a positive and a negative fashion. Temozolomide is the most common chemotherapy used to treat glioblastoma (GBM) and has been shown to have variable effects on immune response to immunotherapy. Therefore, we aimed to determine the immune modulatory effects of temozolomide that would impact response to immune checkpoint inhibition in the treatment of experimental GBM. METHODS: Immune function and antitumor efficacy of immune checkpoint inhibition were tested after treatment with metronomic dose (MD) temozolomide (25 mg/kg × 10 days) or standard dose (SD) temozolomide (50 mg/kg × 5 days) in the GL261 and KR158 murine glioma models. RESULTS: SD temozolomide treatment resulted in an upregulation of markers of T-cell exhaustion such as LAG-3 and TIM-3 in lymphocytes which was not seen with MD temozolomide. When temozolomide treatment was combined with programmed cell death 1 (PD-1) antibody therapy, the MD temozolomide/PD-1 antibody group demonstrated a decrease in exhaustion markers in tumor infiltrating lymphocytes that was not observed in the SD temozolomide/PD-1 antibody group. Also, the survival advantage of PD-1 antibody therapy in a murine syngeneic intracranial glioma model was abrogated by adding SD temozolomide to treatment. However, when MD temozolomide was added to PD-1 inhibition, it preserved the survival benefit that was seen by PD-1 antibody therapy alone. CONCLUSION: The peripheral and intratumoral immune microenvironments are distinctively affected by dose modulation of temozolomide.
引用
- Karachi A, Yang C, Dastmalchi F, et al. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol. 2019. PMID: 30668768. doi:10.1093/neuonc/noz015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。